We tested the following to determine if the synthesized compounds could hit both targets at the same time: (a) early GSK3β activity screening of all produced compounds, (b) Molecular docking study, (c) Selective cytotoxicity on cancer cells and normal blood cells, (d) Anti-tau aggregation in a tau pathology cell model. This evidence concerns the gene GSK3B and cancer.